We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

24 hedge funds and large institutions have $8.07M invested in Titan Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
+24
Holders Change %
–
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
–
Reduced
–
Closed
–
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$3.44M
2
PA
Perceptive Advisors
New York
+$2.36M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$342K
4
Millennium Management
Millennium Management
New York
+$277K
5
Renaissance Technologies
Renaissance Technologies
New York
+$277K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$3.38M +$3.44M +211 New
PA
2
Perceptive Advisors
New York
$2.32M +$2.36M +145 New
Geode Capital Management
3
Geode Capital Management
Massachusetts
$337K +$342K +21 New
Millennium Management
4
Millennium Management
New York
$277K +$277K +17 New
Renaissance Technologies
5
Renaissance Technologies
New York
$275K +$277K +17 New
VKH
6
Virtu KCG Holdings
New York
$225K +$228K +14 New
Bank of America
7
Bank of America
North Carolina
$196K +$195K +12 New
SIM
8
Spark Investment Management
New York
$187K +$195K +12 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$149K +$147K +9 New
Stifel Financial
10
Stifel Financial
Missouri
$147K +$147K +9 New
California Public Employees Retirement System
11
California Public Employees Retirement System
California
$125K +$130K +8 New
Deutsche Bank
12
Deutsche Bank
Germany
$91K +$97.7K +6 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$72K +$65.2K +4 New
Northern Trust
14
Northern Trust
Illinois
$69K +$65.2K +4 New
Goldman Sachs
15
Goldman Sachs
New York
$48K +$48.9K +3 New
TDC
16
Thompson Davis & Co
Virginia
$48K +$48.9K +3 New
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$24K +$32.6K +2 New
TRCT
18
Tower Research Capital (TRC)
New York
$19K +$16.3K +1 New
Wells Fargo
19
Wells Fargo
California
$14K +$16.3K +1 New
BFA
20
BlackRock Fund Advisors
California
$11K +$16.3K +1 New
BCM
21
Blume Capital Management
California
$11K +$16.3K +1 New
Morgan Stanley
22
Morgan Stanley
New York
$10K +$16.3K +1 New
VIA
23
Vantage Investment Advisors
Pennsylvania
$10K +$16.3K +1 New
AIM
24
Arcadia Investment Management
Michigan
$8K +$16.3K +1 New
BA
25
BlackRock Advisors
Delaware
$6K – – –
1
2

TTNP Hedge Fund Activity: Q4 2015 in Review

24 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2015, worth a combined $8.07M.

Buyers outnumbered sellers: 24 funds opened new TTNP positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $3.44M.

  • 24 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2015, up from 0 in Q3 2015.
  • Funds reported $8.07M of Titan Pharmaceuticals stock for Q4 2015.
  • 24 funds opened new Titan Pharmaceuticals positions in Q4 2015 and 0 closed out, a net change of +24 holders.
  • The largest Titan Pharmaceuticals buyer in Q4 2015 was Broadfin Capital, an estimated $3.44M added.

Based on aggregated 13F filings for Q4 2015.